Categories: World

Russia says its Sputnik V COVID-19 vaccine is 92% effective

Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country’s sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

The initial results are only the second to be published from a late-stage human trial in the global race to produce a vaccine that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy.

Russia registered Sputnik V for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

The interim results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, said.

The so-called Phase III trial of the shot developed by the Gamaleya Institute is taking place in 29 clinics across Moscow and will involve 40,000 volunteers in total, with a quarter receiving a placebo shot.

The chances of contracting COVID-19 were 92% lower among people vaccinated with Sputnik V than those who received the placebo, the RDIF said.

That’s well above the 50% effectiveness threshold for COVID-19 vaccines set by the U.S. Food and Drug Administration.

“We are showing, based on the data, that we have a very effective vaccine,” said RDIF head Kirill Dmitriev, adding that it was the sort of news that the vaccine’s developers would talk about one day with their grandchildren.

Russia’s announcement follows swiftly on from results posted on Monday by vaccine developers Pfizer Inc and BioNTech , who said their shot was also more than 90% effective.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology and is designed to trigger an immune response without using pathogens, such as actual virus particles.

The Sputnik V vaccine is designed to trigger a response from two shots administered 21 days apart each based on different viral vectors that normally cause the common cold: human adenoviruses Ad5 and Ad26.

(Reuters)

 

R

Leave a Comment

Recent Posts

Tunisia: Kaïs Saïed and Abdel Latif Jamal Rashid exchange Eid al-Adha greetings

President of the Tunisian Republic, Kaïs Saïed, had a telephone conversation with his Iraqi counterpart,…

2 heures ago

Russian war against Ukraine: Present situation (Ukrainian Embassy in Tunisia)

UKRAINE PEACE SUMMIT SUMMARY On June 16, the inaugural Peace Summit ended in Switzerland. The…

3 heures ago

Norway raises UNRWA funding

The Norwegian government announced Monday that it will raise the economic support for the United…

3 heures ago

Emergency landing of Egyptian plane in Jeddah following death of captain

An unusual and sad situation unfolded last Sunday when an Egyptian plane was compelled to…

3 heures ago

Netanyahu to dismantle Israeli war cabinet

Israeli Prime Minister Benjamin Netanyahu declared the dissolution of the war cabinet to the government…

3 heures ago

Kairouan: he atrociously kills his wife in street, she leaves two children

A tragedy shook Kairouan this Monday, June 17, the second day of Eid el-Kébir. A…

3 heures ago

This website uses cookies.